News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

ZOE Study Reveals Eating a Plant Rich Diet Reduces Risk of Developing COVID-19 and Going to the Hospital

ZOE

Researchers at health science company ZOE, Harvard Medical School, and King’s College London found that people who eat a high quality, gut-friendly diet* are less likely to develop COVID-19 or become severely ill. Alternatively, they discovered that those eating poorer quality diets are more at risk, especially if they live in a more socioeconomically deprived area. The findings are published in medRxiv online as a preprint. Key points from the study: Researchers analyzed data from nearly 600,000 ZOE COVID Study app contributors who completed a survey about the food they ate during Feb 2020 (pre-pandemic), making it the largest study in this space. People with the highest quality diet were around 10% less likely to develop COVID-19 than those with the lowest quality diet, and 40% less likely to become severely ill. This is the first longitudinal study of diet and COVID-19 and the first to show that a healthy diet cuts the chances of developing the disease in the first place. The scale of the study meant researchers were able to adjust for multiple confounding factors, which can be a challenge for studies of smaller sizes. The effect of diet on COVID-19 is independent of other known risk factors, including age, weight, race, ethnicity and underlying health conditions, but was amplified by social inequality. Measuring diet quality While it is already known that diet-related health conditions like diabetes, heart disease and obesity increase the chances of becoming seriously ill with COVID-19, it is not yet clear how the foods people eat affect their risk of catching the virus independently of these factors. To learn more about the interplay between food and health, the team analyzed data from 592,571 UK and US contributors who completed a survey about their eating habits within the ZOE COVID Study app. Based on analysis of symptoms or PCR test results reported in the app, 31,815 contributors (19%) ultimately caught COVID-19. Rather than looking at specific foods or nutrients, the survey was designed to look at broader dietary patterns which are reflective of how we actually eat. The survey produced a ‘diet quality score’ that reflected the overall merit of each person’s diet. Diets with high quality scores were found to contain plant-based foods such as fruits, vegetables, whole grains and nuts, as well as oily fish, healthier fats like olive oil, less processed foods and refined carbohydrates. High quality diet scores were also linked with a ‘healthier’ and a more diverse gut microbiome, which was also associated with a wide range of favorable health outcomes, including reduced inflammation and body fat and improved levels of blood lipids and glucose. For these aforementioned reasons, higher quality scoring diets were also referred to as ‘gut-friendly’ diets. A low diet quality score is associated with diets high in ultra processed foods and low amounts of plant-based foods, like fruit and vegetables. Connecting diet and COVID-19 risk The researchers found that people who ate the highest quality diet were around 10% less likely to develop COVID-19 than those with the least nutritious diet and 40% less likely to become severely ill if they developed COVID-19. Recent research on a smaller cross-sectional sample has shown that people who eat a plant-based or pescatarian** diet are less likely to become severely ill with COVID-19. However, this is the first study to show that a healthier diet actually reduces the chances of developing the disease in the first place. Importantly, the relationship between diet quality and COVID-19 risk still remained after accounting for all potential confounding factors. Factors included age, body mass index (BMI), ethnicity, smoking, physical activity and underlying health conditions. Mask-wearing habits and population density were also considered. Strikingly, the impact of diet was amplified by individual life situations, with people living in low-income neighborhoods and having the lowest quality diet being around 25% more at risk from COVID-19 than people in more affluent communities who were eating in the same way. Based on these results, the researchers estimate that nearly a quarter of COVID-19 cases could have been prevented if these differences in diet quality and socioeconomic status had not existed. This further highlights that improved access to nutritious, healthier food could be substantive for bettering public health, especially among the underprivileged members of the community. Professor Tim Spector, lead scientist at ZOE COVID Study and professor of genetic epidemiology at King’s College London, said: “These findings chime with recent results from our landmark PREDICT study, showing that people who eat higher quality diets (with low levels of ultra-processed foods) also have a healthier collection of microbes in their guts, which is linked to better health. You don’t have to go vegan, but getting more diverse plants on your plate is a great way to boost the health of your gut microbiome, improve your immunity and overall health, and potentially reduce your risk from COVID-19.” Dr Sarah Berry, study co-lead and associate professor in nutritional sciences at King’s College London, said: “For the first time we’ve been able to show that a healthier diet can cut the chances of catching COVID-19, especially for people living in the poorest areas. Access to healthier food is important to everyone in society, but our findings tell us that helping those living in more deprived areas to eat more healthily could have the biggest public health benefits.” Professor Andrew Chan MD, MPH, gastroenterologist and director of epidemiology at Massachusetts General Hospital, and professor at Harvard Medical School, said: “ Diet quality is an established risk factor for many conditions that are known to have an inflammatory basis. Our study demonstrates that this may also hold true for COVID-19, a virus which is known to provoke a severe inflammatory response. We also highlight how diet quality is also an important social determinant of health. COVID-19 has laid bare how such social determinants underlie the severe racial and socioeconomic disparities in COVID-19 risk that we and others have documented.” Jonathan Wolf, CEO of ZOE, added: “At ZOE we’re using the latest data science to unpick the complex connections between diet and health, bringing together our expertise in COVID-19 and nutrition to help improve health for all.” NOTES TO EDITORS For more information about the ZOE COVID Study app or to request an interview with Professor Tim Spector, please contact Eleanor Griffiths: +44 (0)7950 335916 eleanor@joinzoe.com For more information about ZOE or to request an interview with Jonathan Wolf, please contact; Fiana Tulip: fiana@joinzoe.com Preprint available here: Diet quality and risk and severity of COVID-19: a prospective cohort study. The research team includes scientists from: King’s College London; Massachusetts General Hospital, Harvard Medical School and the Harvard T.H. Chan School of Public Health, Boston, USA; The Broad Institute, Cambridge, USA; UTHealth, Texas, USA; Lund University, Sweden; ZOE Global Ltd. *A gut-friendly diet explained: A high quality diet contains more plant-based foods such as fruits, vegetables, whole grains and nuts as well as oily fish and healthier fats like olive oil and less processed foods and refined carbohydrates. This diet quality score is associated with a ‘healthier’ more diverse gut microbiome, which in turn is associated with a wide range of favorable health outcomes, including lower inflammation and body fat and improved blood lipids and glucose. **A pescatarian diet is predominantly vegetarian but includes fish and seafood. About ZOE ZOE is a healthcare science company helping people understand their body’s responses to food. By using machine learning combined with large scale human studies, ZOE is decoding the impact of nutrition on health. ZOE leads the PREDICT Studies and the ZOE COVID Study, which are the world’s largest community powered research programs of their kind in nutrition and COVID-19 respectively. Located in London and Boston, ZOE was founded by Professor Tim Spector of King’s College London, data science leader Jonathan Wolf and entrepreneur George Hadjigeorgiou. ZOE was named one of the Deloitte Fast 50 Rising Stars in 2019 for the company’s contribution to science enabled by technology and machine learning.For more information on ZOE’s mission and science, visit joinzoe.com About ZOE COVID Study The ZOE COVID Study is a not-for-profit initiative that was launched at the end of March 2020 to support vital COVID-19 research. The app was launched by health science company ZOE with scientific analysis provided by King’s College London. With 4 million contributors globally, the study is the world’s largest ongoing study of COVID-19 and is led by ZOE Co-Founder and King’s College London Professor, Tim Spector. The team has published over 20 research papers since March, most notably in Nature Medicine. To date the app is funded by the Department of Health and Social Care. The funding was awarded to enable the app to continue collecting data from its 4million+ users to help the UK government's response to COVID-19 and beyond. The app provides unique insight on asymptomatic and symptomatic information across the UK with 1.2 million logging on a weekly basis. For more information on The COVID Symptom Study app visit covid.joinzoe.com. Contact Details ZOE Fiana Tulip +1 817-691-3031 fiana@joinzoe.com Company Website https://www.joinzoe.com

July 13, 2021 09:13 AM Eastern Daylight Time

Image
Article thumbnail News Release

NextFerm Technologies obtains Regulatory Approval to market Astaferm® Astaxanthin Antioxidant in Canada

NextFerm Technologies Ltd.

NextFerm Technologies (TASE:NXFR), a food-tech company developing ProteVin™, a vegan, yeast-based, non-GMO protein alternative and other innovative yeast-based nutrients, today announced that Health Canada has granted a regulatory marketing approval for Astaferm®, its innovative fermented astaxanthin antioxidant in the form of Gummies. This is the only fermented astaxanthin with no odor and flavor. Along with the receipt of Astaferm®’s license approval (NPN - Natural Product Number), the company is preparing for the launch of several applications of Astaferm® in North America, including for Immunity support, which is a growing segment due to the Covid-19 pandemic. The Company has already supplied initial quantities of Astaferm® in Canada and is currently in dialogues with potential customers. Astaferm® has a US Self GRAS regulatory approval and was launched in the US at the end of 2020. The product is in early stages of sales, by well-known US dietary supplement brands, such as Carlson Labs and Purity Products. Since Astaferm® is flavorless and odorless, the Gummies application constitutes a significant differentiation from other astaxanthin products available on the market, produced from algae with fishy odor, and therefore applied mainly in soft-gels. NextFerm currently prepares to expand the marketing of Astaferm® for additional indications such as immune system support, as well as expanding into additional serving forms, such as water-dispersible powder for food and beverages, and fermented Astaferm® oil for soft-gels with competitive pricing. Boaz Noy, Chief Executive Officer of NextFerm, said, “The regulatory approval received for Astaferm® in Canada strengthens our presence in the North American dietary supplement market. This emphasizes Nextferm's ability to bring innovative nutritional ingredients from R&D to commercialization and sales. We have already started with an initial supply of the product to a customer in Canada and anticipate further launches in light of the differentiation with competing algae-based products that have fishy odor. This is thanks to a unique value proposition that combines a high astaxanthin concentration, without flavor and odor, which allows it to be integrated in delicious gummies and other food applications. At the same time, we are progressing according to our plan for the commercial launch of ProteVin ™, our vegan protein, in 2022.” About NextFerm Technologies NextFerm Technologies, traded on the Tel Aviv Stock Exchange (TASE:NXFR) is a food-tech company engaged in the research, development, manufacturing and marketing of innovative, functional and vegan yeast-derived, non-GMO protein alternatives for various applications in the food and food supplement markets and the growing market for animal-derived protein alternatives. NextFerm's flagship product is ProteVin™, a vegan, yeast-derived protein alternative with nutritional value that is similar to animal-derived protein and a neutral flavor, with no aftertastes that are typical of plant-based protein. ProteVin™ is designed for a variety of categories in the alternative protein market, which is estimated at $13 billion, with an annual growth rate of 10%, including milk and dairy substitutes, meat substitutes and additional categories such as infant nutrition, adult nutrition, and sports nutrition. NextFerm is gearing up for commercialization of the product in the US in 2022. Another product currently being sold is Astaferm®, an innovative astaxanthin-based antioxidant derived from yeast that has been sold in the US since the end of 2020 through well-established and leading brands in the food supplement market in the US. The company has additional products which have been licensed to Lallemand, a global giant focused on yeast. For more information, visit the NextFerm website at: www.nextferm.com Legal Notice Regarding Forward-Looking Statements This announcement also includes forecasts, projections, assessments, estimates and other information which refer to future events and matters, the realization of which is uncertain and not exclusively under the Company’s control (forward-looking information). The main facts and data used to support this information are facts and data regarding the current position of the Company and its businesses (including the scope of sales and levels of profitability, manpower, commercial engagements and more), facts and data regarding the current global position of the Company’s operating segments (including industry-specific financial developments, environmental regulatory developments, the competitive environment, technological developments, the reinsurance market and more), and macro-economic facts and data (including the economic situation both in Israel and around the world, yields in the capital markets, social and state developments and more), all as known by the Company when publishing this announcement. The forward-looking information included above in this announcement is significantly based upon, in addition to the existing information held by the Company, on the Company’s current assessments and expectations of future developments vis-a-vis each one of the aforementioned parameters, and the interconnectedness of each one of these developments. The Company has no certainty that its forecasts and assessments will indeed eventuate, and the Company’s operating results may be materially different than the results assessed or implicit based on that set forth above, inter alia, as a result of a change in any of the aforementioned factors. Contact Details NextFerm Technologies Ltd. Yossi Ohana - Chief Financial Officer +972 54-771-5893 yossio@nextferm.com Investor and Media Contact Meirav Gomeh-Bauer +972544764979 meirav@bauerg.com Company Website https://www.nextferm.com/

July 12, 2021 12:51 PM Eastern Daylight Time

Article thumbnail News Release

New Website Created by Quidel Corporation Provides Consumers With Information and Easy-to-Understand Answers Regarding Lyme Disease

Quidel Corporation

Americans looking for information regarding Lyme disease, often referred to as the “epidemic within the pandemic,” now have a new and trusted resource in which to rely with the launch of LymeDiseaseAnswers.com. Created by Quidel Corporation, the website provides consumers with the peace of mind that comes with increased knowledge of the prevalence, causes, warning signs, symptoms and advances in the testing of Lyme disease, which afflicts nearly 480,000 people across the country each year. “Lyme disease can strike anyone of any age, especially those who spend time in wooded or grassy areas or who play sports on grass fields in high-risk areas of the country,” said Cheryl Miller, vice president of new market development for Quidel. “People are rightfully concerned about contracting Lyme disease and want to know how to avoid it, especially now with Americans spending more and more time outdoors as we emerge from the COVID-19 pandemic. We’ve created LymeDiseaseAnswers.com as a consumer-friendly and straight-talk place where people can easily find the information they are seeking.” The new website, created in tandem is Quidel’s strategic and creative partner breakwhitelight, contains answers to frequently asked questions, easy-to-understand infographics showing where Lyme disease is most prevalent and how it is contracted, the latest statistics and clinical research taking place regarding the disease, and links to additional resources on the subject. Also housed on the site is a series of recently produced “Quick Takes”—attention-grabbing educational videos that help consumers and health care professionals alike enhance their knowledge of Lyme disease by providing the information and up-to-the-minute data needed to confront this disease quickly and clearly. Quidel is the diagnostic health care manufacturer behind the industry’s most rapid and reliable in-office test for Lyme disease, the Sofia 2 Lyme FIA test. This test provides a patient as well as his or her physician with indicative results within minutes as opposed to days, which has historically been the norm. Performed in the privacy of a doctor’s office or local clinic, it is also the only test that can get results from a simple finger prick of blood. Given that the vast majority of patients tested are negative, not having to wait days for test results allows physicians and nurse practitioners to more rapidly treat those patients with positive results while more quickly pursuing other diagnosis and treatment for those who test negative. While just launching this month, LymeDiseaseAnswers.com has already been honored for excellence by the renowned MarCom Awards, an international creative competition that recognizes outstanding achievement by marketing and communications professionals, both corporate and agency. LymeDiseaseAnswers.com received MarCom’s highest award—its Platinum Award—while competing against more than 6,500 entries from the United States and several foreign countries. About Quidel Corporation Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand names Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’s comprehensive product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. With products made in America, Quidel’s mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities and the world. For more information about Quidel, visit quidel.com. Contact Details Jim Yeager +1 818-264-6812 jim@breakwhitelight.com Company Website http://Quidel.com

July 12, 2021 09:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

Cyvatar Takes Home Top Prize in 2021 Fortress Awards

Cyvatar

Cyvatar today received more industry accolades as it was named a winner in network security by the Business Intelligence Group for its innovative Cybersecurity-as-a-Service (CSaaS) offering as part of the 2021 Fortress Cybersecurity Awards. The Fortress awards program identifies and rewards the world’s leading companies and products that are working to keep data and electronic assets safe among a growing threat from hackers. “2021 is rapidly becoming the toughest year for cybersecurity professionals and as our reliance on networks continues to accelerate, our identities and data have quickly become global currency, so security is more important than ever,” said Maria Jimenez, chief nominations officer at the Business Intelligence Group. “We are proud to recognize all of our winners and finalists who are on the frontlines of the effort to prepare, defend and respond to this growing threat.” Cyvatar’s proprietary ICARM method guarantees proper installation, configuration, assessment, remediation, and maintenance for every Cyvatar technology solution so that organizations actually achieve better protection and resilience from their investments And because Cyvatar’s method is continuous, it protects against attack vectors that haven’t even surfaced yet. “It’s continued validation of our unique CSaaS model that industry peers recognized Cyvatar again for exceptional leadership and innovation,” said Cyvatar Co-Founder and Chief Product and Strategy Officer Craig Goodwin. “As the first subscription-based CSaaS company to deliver effortless, affordable cybersecurity, we enable our members to protect confidential information with the people, processes, and technology essential to ensure they get value from their security tools, from conception and strategy to implementation and maintenance. No other provider delivers holistic security at price points that work for any size customer and guaranteed value that allows customers to cancel anytime.” Cyvatar CSaaS levels the playing field by democratizing cybersecurity and making the best protection accessible and affordable for every size organization, even if they have no cybersecurity expertise in-house. If your organization needs award-winning cybersecurity, Cyvatar can help. About Cyber Defense Magazine With over 5 Million monthly readers and growing, and thousands of pages of searchable online infosec content, Cyber Defense Magazine is the premier source of IT Security information for B2B and B2G with our sister magazine Cyber Security Magazine for B2C. We are managed and published by and for ethical, honest, passionate information security professionals. Our mission is to share cutting-edge knowledge, real-world stories and awards on the best ideas, products and services in the information technology industry. We deliver electronic magazines every month online for free, and special editions exclusively for the RSA Conferences. CDM is a proud member of the Cyber Defense Media Group. Learn more about us at https://www.cyberdefensemagazine.com and visit https://www.cyberdefensetv.com and https://www.cyberdefenseradio.com to see and hear some of the most informative interviews of many of these winning company executives. Join a webinar at https://www.cyberdefensewebinars.com and realize that infosec knowledge is power. About Cyvatar Cyvatar is committed to effortless cybersecurity for everyone. As the industry’s first subscription-based, cybersecurity-as-a-service (CSaaS) company, it’s our mission to transform the way the security industry builds, sells, and supports cyber solutions. We empower our members to achieve successful outcomes by providing expert advisors, proven technologies, and a strategic process roadmap to guarantee results that map to their business drivers. Our approach is rooted in proprietary ICARM (installation, configuration, assessment, remediation, maintenance) methodology that delivers smarter, measurable security solutions for superior compliance and cyber-attack protection faster and more efficiently, all at a fixed monthly price. And because we’re a subscription, members can cancel anytime. Cyvatar is headquartered in Irvine, California with locations around the world. Begin your journey to security confidence at CYVATAR.AI and follow us on LinkedIn and Twitter. Contact Details Cyvatar KC Higgins +1 303-434-8163 kc@cyvatar.ai Cyber Defense Magazine April Palanca +18338449468 Company Website https://cyvatar.ai/

July 07, 2021 11:51 AM Eastern Daylight Time

Article thumbnail News Release

Introducing YuCALM®, Natural Calming Chews for Stressed or Anxious Dogs

Lintbells

Lintbells, manufacturer of leading hip and joint supplement for dogs, YuMOVE®, is excited to announce its latest in natural* health products with the launch of YuCALM®. Available on Chewy.com, YuCALM® ONE-A-DAY chews for dogs of all sizes, contains science-backed ingredients to help dogs cope with stress and anxiety. “Many dogs feel anxious on a daily basis or are fearful toward specific triggers such as thunderstorms, fireworks, or new situations like owners returning back to the office,” said John Howie, CEO and co-founder of Lintbells. “By supporting natural calming pathways in the brain, YuCALM® ONE-A-DAY is a safe and effective way to reduce stress and support calm behavior.” Easy to use format. YuCALM® ONE-A-DAY comes in a handy tasty bite dogs love, that makes feeding a breeze. Lemon balm helps dogs feel more relaxed, soothing stress and encouraging calming behavior. L-Theanine offers natural calming properties that support the production of calming compounds such as serotonin. B Vitamins support healthy brain function, reducing excitability and improving concentration. Proprietary blend of natural fish protein hydrolysates helps calming signals locate the right spot in the brain. “We recommend pets be on a daily regimen of YuCALM® approximately four to six weeks in advance of any expected triggering events such as holiday celebrations, major traveling, or family members heading back to school,” adds Howie. “We’re thrilled to offer pet owners a safe and effective solution for their anxious four-legged friends.” Product samples, images, and veterinary and expert interviews available upon request. *Over 90% of ingredients natural. For the full definition please visit yumove.com/natural. About Lintbells Lintbells, the UK's #1 Vet Recommended Dog Joint Supplement company, currently helps more than 1 million dogs across Europe and the United States. In March 2019, Lintbells officially entered the US Market with the introduction of their most popular product abroad, YuMOVE Soft Chews. This joint supplement promotes joint and cartilage health in dogs of all breeds and sizes. Made from all-natural, human-grade, non-GMO ingredients, the secret to YuMOVE Soft Chews' success comes from Lintbells own ActivEase® Green Lipped Mussel (or GLM). GLM, a superfood derived from the purest sources in New Zealand, is an essential ingredient with extraordinary properties that improves joint function, mobility, and reduces discomfort in our dogs. This unique ingredient, rich with more Omega 3s than any other GLM, is naturally anti-inflammatory, meaning our dog's stiff joints are eased naturally. To learn more, visit www.yumove.com Contact Details The Impetus Agency Jamie Baxter +1 775-322-4022 jamie@theimpetusagency.com Company Website https://yumove.com/

July 07, 2021 06:12 AM Pacific Daylight Time

Article thumbnail News Release

GROUNDWORK BIOAG EXPANDS LEADERSHIP TEAM FOR GLOBAL GROWTH OF MYCORRHIZAL PLATFORM

Groundwork BioAg

• Former ICL Fertilizers and Chemicals CEO Hanan Dor Joins to Lead Agriculture Business • Co-Founder Dan Grotsky to Lead Expansion of Cannabis and Growth Initiatives Groundwork BioAg ® announced today that the company has expanded its leadership team to directly align with its key growth markets: mainstream agriculture and cannabis, in response to increased demand for its regenerative agriculture products. Former Chief Executive Officer of ICL Fertilizers and Chemicals, a subsidiary of ICL Group LTD, Hanan Dor has joined the company as Chief Commercial Officer, responsible for expanding the agriculture business. He brings more than 35 years of experience leading global business development, marketing and sales for sustainable specialty fertilizer plant nutrition. During his time in leadership roles, ICL tripled its global business and expanded in key commodity agriculture markets, including China and India. Co-Founder Dan Grotsky is named Chief Growth Officer, responsible for expanding the cannabis business and growth initiatives, including sustainability and carbon markets. Since Groundwork BioAg’s inception in 2014, Grotsky led the development of globally recognizable brands, Rootella ® for row, organic and specialty crops, and DYNOMYCO ® for cannabis. His shift in responsibility reflects the company’s goal to build upon this foundation and accelerate its market leadership position in bioagriculture. “We’re thrilled to attract an industry leader like Hanan to our leadership team. Together, I believe Groundwork BioAg is well positioned to continue our rapid growth trajectory,” said Dr. Yossi Kofman, Co-Founder and CEO of Groundwork BioAg. “Along with insights from the specialty fertilizer industry, Hanan shares our passion for mycorrhiza – the queen of biologicals – and understands its central role to building a bio-platform accessible to farmers around the world. Coupled with Dan’s vision for these brands and the dedication of our entire team, I am confident we will deliver upon our goals.” Groundwork BioAg’s mainstream ag business delivered record sales in both the 2019 and 2020 growing seasons and doubled its cannabis business. In May, the company secured new funding to accelerate mass production of its highly concentrated, cost-effective mycorrhizal inoculants and expand its technology platform to support ongoing innovation. In addition to increasing yield, mycorrhizae improve sustainability by reducing dependency on phosphorus fertilizer and improving carbon sequestration in soil. Through distribution partnerships across five continents, Groundwork BioAg is helping farmers improve the efficiency and profitability of major crop production, including corn, soybeans, grains, bio-energy crops, vegetables and cannabis. About Groundwork BioAg Groundwork BioAg, a global bioagriculture company, leverages the natural power of mycorrhizal fungi to improve the productivity, sustainability and profitability of commercial agriculture and expand regenerative agriculture practices. Groundwork BioAg is the first to use innovative techniques to solve challenges inherent in high-volume mycorrhizal inoculant production. We will not rest until every hectare of arable land is protected by mycorrhizae and every farmer benefits from higher crop yields while preserving our soils. For more information, visit www.groundworkbioag.com. Contact Details AgTech PR Jennifer Goldston +1 816-260-0040 jennifer@agtechpr.com Company Website https://www.groundworkbioag.com

July 07, 2021 07:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

What You Need to Know About Heart Disease

YourUpdateTV

As the world looks with hope to the light at the end of the COVID-19 tunnel, there lies another ongoing health crisis that, according to the American Heart Association (AHA), kills more Americans than anything else: heart disease. Recently, leading cardiologist and Director of Cardiology at State of the Art Cardiology, Dr. John Osborne, teamed with his patient Mike Hodge on a nationwide satellite media tour to discuss managing cardiovascular risk. A video accompanying the announcement can be found here: https://youtu.be/XKKKCVCofew In the last year, heart disease claimed more than 690,000 lives in the U.S., which is staggeringly more than the reported 345,000 lives lost to COVID-19, according to data from the Centers for Disease Control. While the prevalence of the disease – and incredible amounts of research – would lead many to think the risks and standard practices would be widely known, the overwhelming amount of information and data can actually make it harder to assess risk and treatment options, which can be confusing for physicians and patients alike. For example, many people are unaware that after a failed outcomes study, the FDA revoked the approval of a class of drugs called fenofibrates — such as TriCor ® (fenofibrate) and Trilipix ® (fenofibric acid) — concluding that fenofibrates should not be used in combination with statins for CV risk reduction because the risks outweigh the benefits. As a result, millions of patients at risk of heart attack or stroke may be unknowingly receiving medications that have not been shown to reduce cardiovascular (CV) risk on top of statins. According to Dr. Osborne, patients who are taking a fenofibrate, in addition to a statin, are taking a drug that has not shown CV benefit and instead just exposes them to the potential risks of these medicines which outweigh the benefits. For more information, visit itscleartomenow.com About Dr. John Osborne: Dr. Osborne has been recognized as a Fellow of the American College of Cardiology and a Fellow of the National Lipid Association. His clinical interests include preventive cardiology, metabolic syndrome and diabetes, hypertension, congestive heart failure, cholesterol disorders, coagulation disorders, and cardiovascular genetics. He is the founder and director of State of the Heart Cardiology in Dallas, Texas and is currently the National Director of Cardiology, Preventive Cardiology, and Lipidology for the Low T Centers and HerKare. About YourUpdateTV: YourUpdateTV is a social media video portal for organizations to share their content. It includes separate channels for Health and Wellness, Lifestyle, Media and Entertainment, Money and Finance, Social Responsibility, Sports and Technology. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

July 06, 2021 02:00 PM Eastern Daylight Time

Video
Article thumbnail News Release

Motiva launches a ‘life changing’ product, the first-ever clinically proven to help improve Alzheimer’s patients

Fine Hygienic Holding

Motiva Neuro Booster offers higher absorption of six key functional foods New product is clinically proven to improve brain health Worldwide, approximately 44 million people suffer from Alzheimer’s disease and approximately 2.5 million suffer from Multiple Sclerosis (MS) today. With the former expected to rise to 115 million cases by 2050 as well as being the leading cause of institutionalization among the elderly, it remains the only disease on the top 10 list of killers that has no cure, preventative measure, or medication to delay progression. Similarly, MS therapies are noncurative, and except for interferon-based disease-modifying therapies, nearly all are associated with a risk of potentially life-threatening complications. Additionally, MS patients experience a multitude of symptoms and frequent treatment side effects causing significant impairment in all phases of life, including cognition and mood. However, there is hope. The brain, like every other organ in the body, needs essential nutrients to function properly. Dr. John E. Lewis, from the Department of Psychiatry and Behavioural Sciences at the University of Miami Miller School of Medicine, one of the world’s leading experts in nutrition and dietary supplements, has been conducting research on how certain key nutrients can help the brain, with a study on Alzheimer’s patients. His study was a first great step in demonstrating the power of specific nutrients in the face of a serious brain health challenge. As part of the study, each subject took an aloe polymannose multinutrient complex (APMC), a unique blend of nutrients, polysaccharides, phytochemicals, molecules, and elements that are typically uncommon or even missing from the modern diet, for 12 months. The findings at the end of the study were nothing short of remarkable, with the team demonstrating significant and sustained improvements in cognitive function and inflammatory status and a significant increase in the production of stem cells, which may lead to neuro-regeneration, as well as a correlation between cognitive and immune functioning. Unlike research on Alzheimer’s medications, which demonstrate at best only a slowing of disease progress, this product actually showed IMPROVEMENT of cognitive function of Alzheimer’s patients. On learning of this research, Fine Hygienic Holding, behind its Motiva brand of science-based supplements, teamed up with Dr. Lewis to develop the MOTIVA Neuro Booster, a new all-natural product based on the formula that has been clinically proven to improve cognitive function in all, including those with Alzheimer’s. Designed, created, and developed by Dr. Lewis, the MOTIVA Neuro Booster is a powerful combination of six functional foods typically uncommon or even missing from the modern diet, including the very potent acemannan from aloe vera. This unique blend of nutrients, phytochemicals, and polysaccharides, all 100% natural ingredients, gives the product the highest levels of bioavailability and effectiveness. In layman’s terms, MOTIVA Neuro Booster means higher absorption, less dosage, and hence better value for money, a far better value than many prescription medications. Dr. Lewis firmly believes that this dietary supplement is the real deal for brain health, immune support, and overall wellbeing. “I am extremely proud to team-up with a world-class wellness company like Fine Hygienic Holding to bring Motiva Neuro Booster to the world. This is a product that enhances life and can change the trajectory of diseases, such as Alzheimer’s and MS.” The MOTIVA Neuro Booster’s unique blend of ingredients, often lacking in the modern diet, is highly concentrated and comes in an easy-to-digest powder form, enabling it to be easily absorbed by our bodies. The supplement assists focus, maintains memory, and supports overall brain well-being in addition to being clinically proven to support the immune system. MOTIVA is produced in a GMP-CERTIFIED FACILITY in the USA and is the only supplement of its kind to be recommended by the prestigious Medical Wellness Association, based in Houston, Texas, USA. In clinical testing, users of Neuro Booster have reported improved energy, deeper sleep, a happier mood, sharper focus, heightened awareness, and a better sense of overall well-being. What’s not to like about a product that comes from natural ingredients? The Alzheimer’s study’s first published article is on PubMed. The product’s ability to provide enhanced absorption largely comes from BiAloe®, the most bioavailable source of aloe vera polysaccharides known as acemannan. Found in the inner leaf gel of the aloe plant, it is responsible for most of the health benefits associated with aloe vera. Added to that, ingredients such as stabilized rice bran contains more than 200 amino acids, minerals, and vitamins with significant health properties; sunflower lecithin is rich in choline necessary for brain and heart health; and tart cherry, dioscorea, and citric acid offer a host of health benefits for immunity, cholesterol regulation, and enhancement of key cellular processes. Motiva Neuro Booster is being rolled out globally by Fine Hygienic Holding and can be purchased online for global deliveries via our e-commerce website, TheFineShop.com. About Fine Hygienic Holding: Fine Hygienic Holding (FHH), one of the world’s leading wellness groups and the MENA’s leading manufacturer of hygienic products, serves consumers in more than 80 countries around the world. Originally established as a paper manufacturer, FHH has transformed into a wellness company dedicated to enhancing global health and wellbeing. With its commitment to becoming “the shining star of the Arab FMCG business world,” the Group focuses on wellness, sustainability, state-of-the-art production processes, pioneering CSR programs, and award-winning products. The company offers a diverse array of products including sterilized facial tissues, napkins, kitchen towels, toilet paper, baby diapers, adult briefs, jumbo rolls, as well as away-from-home products to accommodate all types of private and public institutions, in addition to innovative personal protective equipment (PPE), long lasting germ protection solutions and natural nutritional supplements. Contact Details Sean Muir sean.m@actionprgroup.com Company Website https://www.finehh.com/

July 05, 2021 09:02 AM Eastern Daylight Time

Article thumbnail News Release

PCMA v. WEHBI AMICUS BRIEF ADVOCATES FOR STATE REGULATION OF PHARMACY BENEFIT MANAGER INDUSTRY

Alliance for Transparent & Affordable Prescriptions

The Alliance for Transparent and Affordable Prescriptions (ATAP), a coalition of physician and patient advocacy organizations dedicated to exposing the role the pharmacy benefit manager (PBM) industry has on rising prescription drug costs was joined by the Community Oncology Alliance (COA) and American Pharmacies in filing an amicus brief in PCMA v. Wehbi. The case, currently being argued in the 8 th Circuit, Court of Appeals is a challenge to a North Dakota law designed to regulate abusive practices by the PBM industry. The brief prepared by Daniel Geyser of Alexander Dubose & Jefferson LLP on behalf of ATAP, COA and American Pharmacies may be found here. Following a ruling by the United States Supreme Court in Rutledge v. Pharmaceutical Care Management Association ( where ATAP also filed an amicus brief ), many states have begun to explore regulating the PBM industry to lower costs and increase access to therapies. That case resulted in a unanimous 8-0 decision where the Justices agreed that states have the right to impose regulations on PBMs. Despite setbacks in legislatures and the courts, the PBM industry continues to raise challenges to state regulation of their practices and seeks to avoid accountability. ATAP has been an active advocate for patients in a variety of federal and state battles to amplify the voices of patients and physicians – especially as it relates to exposing PBM abuses and their impact on patients’ access to therapies (medications) needed in their treatment. Dr. Robert Levin, ATAP’s President stated, “We see first-hand how the PBM industry drives up costs and interferes with medical care. Doctors, patients, legislators and regulators are all saying, ‘enough is enough’ and fighting back. We appreciate the opportunity to argue on behalf of patients and defend our obligation to them as the Courts once again weigh in on regulating this rogue industry.” “Oncologists remain troubled by the negative impact PBMs have on patient care and role they play in driving up costs,” said Kashyap Patel, MD, president of COA and a practicing medical oncologist at Carolina Blood and Cancer Care Associates in Rock Hill, South Carolina “PBMs are directly responsible for the loss of patient access to affordable, potentially life-saving medications for cancer and other serious diseases. COA is proud to share our voice and support to effort in North Dakota and nationwide to stop PBM abuses.” “PBMs have used their outsized market power to raise community pharmacies costs of operation,” explained Miguel S. Rodriguez, General Counsel at American Pharmacies. “PBMs operate in secrecy and routinely fail to pass along any savings to patients. It is time to shine a light on and regulate this industry.” American Pharmacies is a nation-wide independent pharmacy cooperative that routinely advocates on behalf of independent pharmacies and the patients they serve. ATAP, COA, and American Pharmacies argue in the brief that: “…PBMs engage in harmful practices that impair optimal patient care, distort the free market, and impose serious costs on every major stakeholder in 5 the healthcare industry. States are ideally positioned to attack PBM misconduct; the regulation of healthcare is a traditional state function, and States routinely address market inefficiency and abuse, just as North Dakota did…” “We are optimistic that the Courts will see through the previously hidden profit motives of the PBM industry,” said Dr. Angus Worthing of the American College of Rheumatology, an ATAP member organization. “With each new state law combined with other actions at the federal level, patients, physicians, and policy makers now have the power to effect meaningful change.” “The Courts will surely see, like we all do, that patients are suffering under a system preventing them from obtaining medicine they need – at prices they can afford,” said Dr. Michael Schweitz of the Coalition of State Rheumatology Organizations, an ATAP member organization. “The PBM industry profits significantly off rebates and other schemes while interrupting the provider-patient relationship. It is time to do what is right and allow policymakers to stand up and do the right thing.” “The profit motivations from the PBM industry impact real people in dangerous ways,” Dr. Levin continued. “ATAP members are on the front lines of medical care. We see the struggles and confusion that patients are put through by this completely unnecessary middleman industry. They deserve better – they deserve the truth – not dangerous interference from policies motivated only by profit.” ATAP is working in many states to force the PBM industry to disclose rebate data and encourage transparency and reporting requirements for all entities involved in the prescription drug supply chain – PBMs, insurers, and manufacturers. ### For more information, or to schedule an interview with an ATAP spokesperson please contact Dan Rene at 202-329-8357. Please visit http://www.atapadvocates.com ATAP's mission is to address prescription drugs costs and patient access to affordable treatment by regulating PBM practices and reforming the drug industry through educational outreach and grassroots advocacy initiatives at both the state and federal level. Contact Details Dan Rene +1 202-329-8357 daniel.rene@kglobal.com Company Website http://www.atapadvocates.com

July 02, 2021 08:30 AM Eastern Daylight Time

1 ... 266267268269270 ... 306